PubMed Health⌕ Search

Biomedical subjects

A Roguin

Publications and source records attributed to A Roguin.

At least 19 recordsLinked to original sources
PubMed2000

Long-term prognosis of acute pulmonary oedema--an ominous outcome.

BACKGROUND: Acute pulmonary oedema (APOE) is a major health problem, leading to poor hospital and long-term outcomes. There is a relative paucity of studies describing prognosis of consecutive unsolicited patients diagnosed with APOE and hospitalized in internal medicine departments. AIMS: To describe the clinical profile and outcome (in hospital and 1-year prognosis) of successive unselected patients with APOE, in a prospective observational study. METHODS AND RESULTS: The study population included 150 consecutive unsolicited patients (90 men, 60 women; median age 75 years) with APOE all hospitalized in an internal medicine department, in a 900-bed care centre. Ischaemic heart disease (IHD), hypertension and diabetes were present in 85%, 70% and 52% of patients, respectively. The most common precipitating factors for APOE included high blood pressure (29%), rapid atrial fibrillation (29%), unstable angina pectoris (25%), infection (18%) and acute myocardial infarction (MI; 15%). Eighteen patients (12%) died in hospital, with 82% of these deaths attributed to cardiac pump failure. Predictors for an increased in-hospital mortality included: diabetes (P<0.05), orthopnoea (P<0. 05), echocardiographic finding of depressed global left ventricular systolic function (P<0.001), acute MI during hospital stay (P<0.001), hypotension/shock (P<0.05), and the need for mechanical ventilation (P<0.001). After a median hospital stay of 10 days, 132 patients were discharged home. The 1-year mortality was 40%. Only the presence of pleural effusion was found as a predictor for 1-year mortality. CONCLUSION: Most patients with APOE in this study are elderly, and have IHD, hypertension, diabetes and a previous history of APOE. The overall mortality is high (in-hospital, 12%: 1-year, 40%). Left ventricular dysfunction was associated with high in-hospital mortality, but not with long-term prognosis.

Adult↗
PubMed2000

Prospective evaluation of pulmonary edema.

OBJECTIVES: To describe the clinical profile and hospital outcome of successive unselected patients with pulmonary edema hospitalized in an internal medicine department. DESIGN: Prospective, consecutive, unsolicited patients diagnosed with pulmonary edema. SETTING: An internal medicine department in a 900 tertiary care center. PATIENTS: A total of 150 consecutive unselected patients (90 males, 60 females; median age, 75 yrs). RESULTS: Ischemic heart disease, hypertension, various valvular lesions and diabetes mellitus were present in 85%, 70%, 53%, and 52% of patients, respectively. Acute myocardial infarction at admission was observed in 15% of patients. The most common precipitating factors associated with the development of pulmonary edema included: high blood pressure (29%), rapid atrial fibrillation (29%,) unstable angina pectoris (25%), infection (18%), and acute myocardial infarction (15%). Twenty-two patients (15%) were mechanically ventilated. Eighteen patients (12%) died while in the hospital, and the cause of death was cardiac pump failure in 82%. The median hospital stay was 10 days. Predictors for increase rate of in-hospital mortality included: diabetes (p<.05), orthopnea (p<.05), echocardiographic finding of moderate-to-severely depressed global left ventricular systolic function (p<.001), acute myocardial infarction during hospital stay (p<.001), hypotension/shock (p<.05), and the need for mechanical ventilation (p<.001). CONCLUSIONS: Most patients with pulmonary edema in the internal medicine department are elderly, having ischemic heart disease, hypertension, diabetes, and a previous history of pulmonary edema. The overall mortality is high (in-hospital, 12%) and the predictors associated with high in-hospital mortality are related to left ventricular myocardial function. The long median hospital stay (10 days) and the need for many cardiovascular drugs, impose a considerable cost in the management and health care of these patients.

Adolescent↗
PubMed1999

Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.

BACKGROUND: The coronary artery collateral circulation may be beneficial in protecting against myocardial ischemia and necrosis. However, there is a tremendous interindividual variability in the degree of new collateral formation in patients with coronary artery disease. The basis for this interindividual heterogeneity is not understood. In this study we test the hypothesis that failure to generate collateral vessels is associated with a failure to appropriately induce with hypoxia or ischemia the angiogenic factor, vascular endothelial growth factor (VEGF). METHODS AND RESULTS: We correlated the VEGF response to hypoxia in the monocytes harvested from patients with coronary artery disease with the presence of collaterals visualized during routine angiography. We found that there was a highly significant difference in the hypoxic induction of VEGF in patients with no collaterals compared with patients with some collaterals (mean fold induction 1.9+/-0.2 versus 3.2+/-0.3, P<0.0001). After subjecting the data to ANCOVA, using as covariates a number of factors that might influence the amount of collateral formation (ie, age, sex, diabetes, smoking, hypercholesterolemia), patients with no collaterals still have a significantly lower hypoxic induction of VEGF than patients with collaterals. CONCLUSIONS: This study provides evidence in support of the hypothesis that the ability to respond to progressive coronary artery stenosis is strongly associated with the ability to induce VEGF in response to hypoxia. The observed interindividual heterogeneity in this response may be due to environmental, epigenetic, or genetic causes. This interindividual heterogeneity may also help to explain the variable angiogenic responses seen in other conditions such as diabetic retinopathy and solid tumors.

Cell Hypoxia↗
PubMed1999

First clinical experience with the premounted balloon-expandable serpentine stent: acute angiographic and intermediate-term clinical results.

The beStent-Artist coronary stent is a newly developed, stainless steel coronary stent with a serpentine tubular design and terminal stent markers, premounted on a semicompliant balloon. During this pilot evaluation we aimed to test the acute clinical and angiographic results, short-term (30 days) and 6-month clinical results. A total of 57 stents were used to treat 43 lesions in 40 patients. Deployment strategy included predilatation, stent deployment, balloon repositioning to match the distal end of the balloon to the distal stent marker, and subsequent 12-14 atm postdilatation. There were two cases of stent dislodgment, but no procedural complications. In four cases, stent recrossing with another balloon was necessary. In two of these cases, distal dissections were observed and treated with another stent. The minimal lumen diameter (MLD) increased from 0.84+/0.52 mm at baseline to 2.7+/-0.62 mm at the end of the procedure (a corresponding decrease in diameter stenosis from 78.6 > 16.4 to 18.2+/-10.7%). The acute gain was 1.89+/-0.61mm. No adverse events occurred by 30 days. During six months, 7/40 (18.5%) of patients required target vessel revascularization due to in-stent restenosis. In summary, the premounted beStent-Artist can be delivered and deployed with favorable immediate results and high success rate with favorable long-term recurrent event rates.

Adult↗
PubMed1999

Continued expansion of the nitinol self-expanding coronary stent: angiographic analysis and 1-year clinical follow-up.

BACKGROUND: This study sought to report the first-year clinical outcome with the nitinol self-expanding coil stent and to provide angiographic data on the effect of self-expansion during implantation and follow-up. Self-expanding stents do not reach their nominal diameter at implantation. The long-term effects may therefore depend, in part, on continued expansion after initial implantation. METHODS: Between January 1995 and January 1996, 86 stents were deployed in 64 patients for indication of suboptimal results. All patients were clinically followed up for 1 year, and 72% had follow-up angiography. RESULTS: The majority (55%) of the lesions were class B2 or C. Balloon angioplasty increased the minimal lumen diameter from 1.07 +/- 0.73 mm to 2.24 +/- 0.57 mm; stent deployment further increased the diameter to 2.63 +/- 0.48 mm, and within-stent balloon dilatation to 2.96 +/- 0.62 mm. Angiographic follow-up performed at 7.8 +/- 1.1 months (range 7-9 months) showed that the minimal lumen diameter was 2.15 +/- 0.80 mm (late lumen loss of 0.81 +/- 0.69 mm), and the mean stent diameter expanded to 3.58 +/- 0.48 mm (self-expanding late stent gain of 0.62 +/- 0.55 mm). The extent of this expansion was inversely related to the late lumen loss (r = 0.67, slope 0.81, P <.01). At 1 year 51 (80%) of 64 patients were event free; 3 had undergone coronary artery bypass grafting, 2 had had a myocardial infarction, and 9 had repeat angioplasty. In the subgroup of a simple lesion (<15 mm) covered by 1 stent, 18 (86%) of 21 patients were event free. CONCLUSIONS: The self-expanding nitinol stent exerts its acute effect on minimal lumen diameter through its intrinsic radial force aided by balloon expansion. The stent continues to expand until it reaches its nominal diameter over the follow-up period. The extent of this expansion is inversely related to the late lumen loss, leading to an acceptable rate of long-term clinical events in this first cohort of patients with complex disease morphology.

Alloys↗
PubMed1999

One-year clinical follow-up with the serpentine balloon expandable stent: report of the first 100 patients.

BACKGROUND: We recently reported a high technical and 30-day clinical success rate among the first 100 patients treated with the tubular, serpentine design, stainless steel, balloon-expandable stent (beStent) in Israel. The present study examined the clinical results in these patients after the first year. METHODS: Seventy-eight men and 22 women were included in the study. Previous myocardial infarction, bypass surgery and percutaneous transluminal coronary angioplasty had occurred in 52%, 12% and 26% of the patients, respectively. Diabetes mellitus was present in 30 patients and hypertension in 34 patients. One hundred and forty-eight stents of 15, 25, and 35 mm lengths were used. The indications for stenting were suboptimal results (n = 85), bailout conditions (n = 10) or for the prevention of restenosis (n = 8), and lesion types were A (n = 10), B1 (n = 29), B2 (n = 20), and C (n = 44). All patients were clinically monitored with regular visits at 1, 3, 6, 9 and 12 months. RESULTS: Overall, the 12-month event-free survival rate was 82%. Subacute thrombosis occurred in two patients. There were two non-cardiac deaths, one O-wave myocardial infarction, six elective bypass surgeries and 12 target lesion revascularizations. Event-free survival was significantly higher for those with lesions shorter than 15 mm than for those with lesions longer than 15 mm (90% versus 67%, P = 0.003), and for women compared with men (96% versus 78%, P = 0.02). CONCLUSIONS: The initial experience with the beStent shows favorable long-term results with an overall event rate of 18% for this subset of relatively complex lesions; higher event rates were observed for longer lesions.

Angioplasty, Balloon, Coronary↗
PubMed1999

Interventional cardiology--promises and challenges.

The current explosion in coronary stent use for the treatment of coronary artery disease has helped to better define who really benefits from coronary stenting. It is clear that plain old balloon angioplasty can be at least as efficacious as stenting in certain patient groups. Patients with reference vessel diameter of < 2.5 mm, a small post-stent minimal lumen diameter, lesion length > 30 mm, diabetes mellitus and end-stage renal failure--all associated with a high incidence of diffuse in-stent restenosis--should not be stented routinely. The judicious use of stents in percutaneous revascularization will improve patient outcomes and decrease cost. The progress that has been achieved in coronary stent designs has led to many new questions, such as which patients benefit the most from stenting and whether adjunctive therapies or stent coatings will effectively prevent restenosis. Despite the advances in stent/balloon technology, antiplatelet agents, and interventional operator skill, the problems of in-stent restenosis remain. Novel therapeutic strategies for the management of severe coronary artery disease are evolving rapidly. Radiation therapy shows promise on this front. This therapy may reduce rates of restenosis by inhibiting smooth muscle proliferation and migration. However, important issues regarding the type of radiation and the matter of edge-restenosis are yet to be resolved, and the results of ongoing prospective randomized trials should provide valuable information on the efficacy of this modality. Patients with severe, non-revascularizable coronary artery disease and debilitating symptoms represent another frustrating clinical problem. PMR performed in the cardiac catheterization laboratory may improve symptoms of angina in patients with end-stage coronary artery disease. The early results are propitious. Among patients who have undergone this procedure 80-90% have improved from class IV (the most severe chest pain) to class I or II, enabling them to live relatively normal lives. Most investigators believe that PMR may be used only for those who are unsuitable candidates for percutaneous or surgical revascularization. Finally, gene therapy, by stimulating angiogenesis and improving coronary collateral development, may prove to be the most optimal treatment. Each of these strategies is currently under active investigation to confirm the results of the pilot studies, identify patient subgroups likely to respond to therapy, and determine long-term safety. Together with its challenges, the future of interventional cardiology is indeed bright.

Cardiac Surgical Procedures↗
PubMed1998

Percutaneous closure of a coronary aneurysm with a vein-coated stent.

Coronary artery aneurysm is a rare but recognized complication following percutaneous intervention. We report the formation of such an aneurysm after recanalization with Excimer laser wire of a chronic totally occluded left anterior descending coronary artery and stent implantation and its subsequent treatment using an autologous vein graft-coated stent.

Adult↗
PubMed1998

Long-term follow-up of patients with severe rheumatic tricuspid stenosis.

BACKGROUND: Tricuspid stenosis is a part of the chronically rheumatic heart. Although rare, when tricuspid stenosis does occur, it occurs in the setting of coexistent mitral and aortic valve disease. The natural course of patients with severe tricuspid stenosis is not well defined. The aim of this study is to present close follow-up of patients with chronic rheumatic heart disease and severe tricuspid stenosis. METHODS AND RESULTS: We retrospectively studied 13 patients (11 women and 2 men) with severe tricuspid stenosis who were followed closely for 6 to 31 years. The mean tricuspid pressure gradient ranged from 3 to 9 mm Hg. Twelve patients underwent surgery for mitral and/or aortic valve lesions without complications. Concomitant tricuspid valve surgery was performed on six patients: two De Vega procedures, two Kay plications, and two implantations of Carpentier rings. All these also had leaflet commissurotomy. After surgery, the mean tricuspid gradient decreased in three patients, did not change in two, and increased in one. All 13 patients were treated with diuretics, digoxin, warfarin, and spirinolactone or ACE inhibitors. On their last follow-up visit, every patient had increased jugular venous pressure. Hepatomegaly was found in 6 of 13, leg edema in 4 of 13, and ascites in 1 of 13. CONCLUSIONS: Most tricuspid stenos patients are women with severe mitral and aortic valve disease. After successful repair of the mitral or aortic valve, and regardless of the type of tricuspid valve surgery, severe tricuspid stenosis was found to be very well tolerated by all the patients over many years of follow-up.

Adolescent↗
PubMed1998

beStent--the serpentine balloon expandable stent: review of mechanical properties and clinical experience.

The objective of this study was to present the engineering and clinical aspects of a new balloon expandable coronary stent. A new tubular, serpentine design stainless steel balloon-expandable stent, the beStent, was designed based on clinical requirements for stents and has been clinically evaluated in multiple sites. The stent is featured by terminal gold markers and rotational junctions that assure no shortening upon expansion and lead to orthogonal locking, maximizing radial strength. In terms of methods and results, the stent was clinically evaluated in the framework of a pilot evaluation in a variety of lesion types. The short- and long-term results evaluated during the course of the beStent multicenter pilot evaluation and in our single center study are reported. A variety of patients were included, including patients with long complex lesions, restenosis lesions, and total occlusions. Short-term clinical success with stenting was achieved in more than 97% of the cases. Subacute thrombosis was low in 1% of the cases. Clinical restenosis rates were acceptable with an overall 85% 6 month event free survival. In conclusion, the mechanical features of the stent providing its flexibility, scaffolding properties, radial strength, and absence of shortening were tested in a clinical study, showing that it is safe and effective for treating simple as well as long and complex lesions associated with coronary disease with a relatively low rate of complications.

Adult↗
PubMed1997

Acute and 30-day results of the serpentine balloon expandable stent implantation in simple and complex coronary arterial narrowings.

We report the acute and 30-day results with a new serpentine-design, tubular, stainless steel, balloon-expandable stent (beStent) in the first 100 patients. One hundred forty-eight stents were used to treat 103 narrowings in the left anterior descending (n = 46), left circumflex (n = 20), and right coronary (n = 37) arteries. There were 85 de novo and 18 restenotic lesions (lesion length: < 10 mm [31], 10 to 20 mm [43] > 20 mm [29]; lesion type: A [10] B1 [29], B2 [20], C [44]; total occlusions, 23. More than 1 stent was used in 31 patients for treatment of long lesions that could not be covered by 1 stent. The stents used were 15-mm (n = 106), 25-mm (n = 38), or 35-mm (n = 4) long. Stent implantation strategy involved predilatation, deployment, and high-pressure dilatation, using the same balloon if possible. Clinical in-hospital success was 97% (2 patients had stent thrombosis that was recanalyzed, with myocardial infarction developing in 1, and 1 patient died on day 14 from retroperitoneal bleeding treated with surgery and complicated by sepsis). One-month event-free survival was 96%, with 1 death on day 21 due to hypertensive crisis. There were no other major adverse cardiac events in this first complex cohort of patients. In conclusion, the initial experience with this stent demonstrates its safety and efficiency for treating simple and complex coronary disease, with a relatively low rate of complications. Long-term clinical follow-up awaits further investigation.

Angioplasty, Balloon, Coronary↗